Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.


Service d'Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France; Department of Hematology and Marrow Transplantation, University Federico II of Naples, Naples, Italy. Electronic address: [Email]


Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments.


Allogeneic stem cell transplantation,FLT3 mutated acute myeloid leukemia,Maintenance treatment,Sorafenib,Update,